Clearmind Medicine Announces Publication of International Patent for Novel Therapy Targeting Weight Loss and Fatty Liver Disease

Rhea-AI Summary

Clearmind Medicine (Nasdaq: CMND) announced on March 10, 2026 the publication of an international PCT patent application for a novel, non-hallucinogenic combination therapy pairing MEAI with Palmitoylethanolamide (PEA) targeting weight loss and metabolic dysfunction-associated steatotic liver disease (MASLD).

The company cites a collaboration with NeuroThera Labs and notes market context: global weight-loss drugs valued at ~$37B in 2025 and forecast to reach ~$226B by 2035. The filing is a patent publication, not a granted patent or clinical efficacy readout.

Positive

• International PCT patent publication for MEAI-PEA combination (March 10, 2026)
• Collaboration established with NeuroThera Labs (PEA supplier) and SciSparc-linked partner
• Addresses large markets: obesity (~890 million adults) and MASLD (~30% adults)
• Cites weight-loss drugs market growth from $37B (2025) to $226B (2035)

Negative

• Patent application publication is not an issued patent or enforceable grant
• No clinical efficacy or safety results for the MEAI-PEA combination disclosed
• No financial terms or timelines for commercialization provided

Argus Mar 10 session

-1.96% close to close Open Argus

Details

News Market Reaction – CMND

On Mar 10, the day this news came out, CMND closed 1.96% below the previous close.

Data tracked by StockTitan Argus for the Mar 10 session.

Key Figures

Obesity prevalence: over 890 million adults MASLD prevalence: approximately 30% of global adults Weight loss drugs 2025: $37 billion +2 more

Obesity prevalence

over 890 million adults

Global adults affected by obesity

MASLD prevalence

approximately 30% of global adults

Share of adults with MASLD

Weight loss drugs 2025

$37 billion

Global weight loss drugs market value in 2025

Weight loss drugs 2035

$226 billion

Forecasted market value in 2035

Metabolic market 2035

over $200 billion

Market projected for obesity and MASLD therapies by 2035

Historical Context

5 past events · Latest: Mar 04

5 events

1. Mar 04

   Clinical trial update

   24h Move

   -4.8%

   DSMB unanimously cleared progression to third CMND-100 cohort with 80 mg dose.

2. Feb 19

   Promotional article

   24h Move

   +4.2%

   Paid review highlighted MEAI’s preclinical weight-loss data and patent activity.

3. Feb 09

   Clinical safety data

   24h Move

   -8.2%

   Additional positive topline safety results from second CMND-100 cohort in AUD trial.

4. Feb 06

   Development agreement

   24h Move

   -6.9%

   Agreement with Polyrizon to develop intranasal MEAI hydrogel formulation.

5. Feb 03

   Policy recognition

   24h Move

   -5.8%

   MEAI named in U.S. bill H.R. 7091 expanding veteran access to emerging therapies.

24h Move is the share-price change in the day after each event; other market factors may also have contributed.

Key Terms

metabolic dysfunction-associated steatotic liver disease, MASLD, Patent Cooperation Treaty (PCT), Palmitoylethanolamide, +2 more

6 terms

metabolic dysfunction-associated steatotic liver disease medical

"aimed at treating weight loss and metabolic dysfunction-associated steatotic liver disease (MASLD..."

A common chronic liver condition marked by excess fat in the liver linked to metabolic problems like obesity, diabetes, or high blood pressure; it ranges from harmless fat buildup to inflammation and scarring. Investors care because its high and growing prevalence drives demand for diagnostics, monitoring tools, drugs, and related healthcare services—think of it like a market need created by a widespread health problem that fuels product and treatment opportunities.

MASLD medical

"metabolic dysfunction-associated steatotic liver disease (MASLD, formerly known as fatty liver disease)"

Metabolic dysfunction-associated steatotic liver disease (MASLD) is a chronic condition where excess fat builds up in the liver due to underlying metabolic problems like insulin resistance, obesity, or high blood lipids. Think of the liver like a kitchen filter getting clogged with grease; over time that buildup can reduce function and lead to inflammation or scarring, which matters to investors because it signals a large, growing market for diagnostics, treatments, and related medical services.

Patent Cooperation Treaty (PCT) regulatory

"publication of an international patent application under the Patent Cooperation Treaty (PCT)..."

An international patent filing system that lets an applicant start the patent process in many countries with a single unified application, like submitting one passport-style request instead of separate applications for each country. It matters to investors because PCT filings can preserve and coordinate intellectual property rights globally while a company refines its markets and partners; a robust PCT strategy can protect future revenue streams, signal competitive advantage, and affect valuation and licensing potential.

Palmitoylethanolamide medical

"integrates Clearmind’s proprietary 5-methoxy-2-aminoindane (MEAI) with Palmitoylethanolamide (PEA)..."

Palmitoylethanolamide (PEA) is a naturally occurring fatty molecule produced in the body and sold as a supplement or experimental therapy for reducing pain and inflammation; think of it as a built‑in calming signal that helps quiet irritated tissues. Investors watch PEA because its potential medical benefits, regulatory path (supplement vs. drug), and clinical evidence drive market demand, pricing and the risk/reward of companies developing or selling PEA-based products — similar to how a promising ingredient can change the fortunes of a consumer brand.

neuroplastogen medical

"novel, non-hallucinogenic, second generation, neuroplastogen-derived therapeutics to solve..."

A neuroplastogen is a drug or compound designed to boost the brain’s ability to rewire and form new connections, enhancing recovery or adaptation after injury, stress, or disease. For investors, these molecules matter because they target underlying brain repair processes rather than just masking symptoms, offering the potential for durable benefits in conditions like depression, neurodegeneration, or cognitive decline—akin to giving a tired garden fresh tools to regrow and reshape itself.

GLP-1s agonists medical

"more cost effective option than GLP-1s agonists for obesity and MASLD."

GLP‑1 agonists are medicines that mimic a natural gut hormone to help the body release insulin and reduce appetite, often producing meaningful blood‑sugar control and weight loss. They matter to investors because their clinical benefits can drive large sales, reshape markets for diabetes and obesity treatments, and create winners and losers across drugmakers, insurers and suppliers — much like a popular new smartphone can shift an entire tech industry.

AI-generated analysis. How Rhea-AI works. Not financial advice.

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google

Add on Google Not now

Innovative non-hallucinogenic treatment combines MEAI with Palmitoylethanolamide to address obesity and metabolic dysfunction-associated steatotic liver disease, tapping into a rapidly growing market projected to exceed $200 billion by 2035

Vancouver, Canada, March 10, 2026 (GLOBE NEWSWIRE) -- Clearmind Medicine Inc. (Nasdaq: CMND), (FSE: CWY0) (“Clearmind” or the "Company"), a clinical-stage biotech company focused on the discovery and development of novel, non-hallucinogenic, second generation,  neuroplastogen-derived therapeutics to solve major under-treated health problems, today announced the publication of an international patent application under the Patent Cooperation Treaty (PCT) for a novel combination therapy aimed at treating weight loss and metabolic dysfunction-associated steatotic liver disease (MASLD, formerly known as fatty liver disease). This novel therapy integrates Clearmind’s proprietary 5-methoxy-2-aminoindane (MEAI) with Palmitoylethanolamide (PEA), provided through its collaboration with NeuroThera Labs Inc. (TSXV: NTLX), a subsidiary of SciSparc Ltd. (Nasdaq: SPRC).

The patent publication highlights the potential of this MEAI-PEA combination to offer a safe, non-hallucinogenic neuroplastogen treatment for two major global health challenges: obesity, affecting over 890 million adults worldwide, and MASLD, impacting approximately 30% of the global adult population. Moreover, due to the presumed mechanism of action of the combination, this therapeutic option may offer a safer, easier and more cost effective option than GLP-1s agonists for obesity and MASLD.

"The publication of this international patent is part of our mission to develop innovative, proprietary and transformative therapies for underserved metabolic and neurological conditions," said Dr. Adi Zuloff-Shani, CEO of Clearmind Medicine. "By combining our MEAI platform with PEA from our partners at NeuroThera Labs, we are positioning ourselves to address the escalating demand for effective, tolerable and safe treatments in the obesity and liver health space. This comes at a time when the global weight loss drugs market is experiencing rapid growth, which was valued at approximately $37 billion in 2025 and is forecasted to reach $226 billion by 2035, driven by increasing awareness of obesity as a chronic disease and the need for innovative alternatives to GLP-1 agonists."

About Clearmind Medicine Inc.

Clearmind is a clinical-stage neuroplastogens pharmaceutical biotech company focused on the discovery and development of novel psychedelic-derived therapeutics to solve widespread and underserved health problems, including alcohol use disorder. Its primary objective is to research and develop psychedelic-based compounds and attempt to commercialize them as regulated medicines, foods, or supplements.

The Company’s intellectual portfolio currently consists of nineteen patent families, including 31 granted patents. The Company intends to seek additional patents for its compounds whenever warranted and will remain opportunistic regarding the acquisition of additional intellectual property to build its portfolio.

Shares of Clearmind are listed for trading on Nasdaq under the symbol "CMND".

For further information, visit: https://www.clearmindmedicine.com or contact:

Investor Relations
invest@clearmindmedicine.com

Telephone: (604) 260-1566
US: CMND@crescendo-ir.com

General Inquiries
Info@Clearmindmedicine.com
www.Clearmindmedicine.com

Forward-Looking Statements:

This press release contains “forward-looking statements” within the meaning of the Private Securities Litigation Reform Act and other securities laws. Words such as “expects,” “anticipates,” “intends,” “plans,” “believes,” “seeks,” “estimates” and similar expressions or variations of such words are intended to identify forward-looking statements. For example, the Company is using forward-looking statements when it discusses the potential of this MEAI-PEA combination to offer a safe, non-hallucinogenic neuroplastogen treatment for obesity and MASLD, its mission to develop innovative, proprietary and transformative therapies for underserved metabolic and neurological conditions, how this therapeutic option may offer a safer, easier and more cost effective option than GLP-1s agonists for obesity and MASLD, how it is position itself to address the escalating demand for effective, tolerable treatments in the obesity and liver health space and the expected growth of the global weight loss drugs market.

Forward-looking statements are not historical facts, and are based upon management’s current expectations, beliefs and projections, many of which, by their nature, are inherently uncertain. Such expectations, beliefs and projections are expressed in good faith. However, there can be no assurance that management’s expectations, beliefs and projections will be achieved, and actual results may differ materially from what is expressed in or indicated by the forward-looking statements. Forward-looking statements are subject to risks and uncertainties that could cause actual performance or results to differ materially from those expressed in the forward-looking statements. For a more detailed description of the risks and uncertainties affecting the Company, reference is made to the Company’s reports filed from time to time with the Securities and Exchange Commission (“SEC”), including, but not limited to, the risks detailed in the Company’s annual report on Form 20-F for the fiscal year ended October 31, 2025 and subsequent filings with the SEC. Forward-looking statements speak only as of the date the statements are made. The Company assumes no obligation to update forward-looking statements to reflect actual results, subsequent events or circumstances, changes in assumptions or changes in other factors affecting forward-looking information except to the extent required by applicable securities laws. If the Company does update one or more forward-looking statements, no inference should be drawn that the Company will make additional updates with respect thereto or with respect to other forward-looking statements. References and links to websites have been provided as a convenience, and the information contained on such websites is not incorporated by reference into this press release. Clearmind is not responsible for the contents of third-party websites.

FAQ

AI-generated questions and answers. How Rhea-AI works. Not financial advice.

What did Clearmind (CMND) announce on March 10, 2026 about a new patent?

Clearmind announced the publication of an international PCT patent application for a MEAI-PEA combination therapy. According to the company, the filing covers a non-hallucinogenic neuroplastogen approach targeting obesity and MASLD and reflects a collaboration with NeuroThera Labs.

How does the new MEAI-PEA patent impact Clearmind's CMND development strategy?

The patent publication may strengthen Clearmind's IP position around its MEAI platform. According to the company, it supports development of non-hallucinogenic therapies for obesity and MASLD alongside its collaboration with NeuroThera Labs.

Does the Clearmind (CMND) announcement include clinical trial results for MEAI-PEA?

No, the announcement does not include clinical efficacy or safety data for the MEAI-PEA combination. According to the company, the news relates to a patent publication and not to completed clinical readouts or regulatory approvals.

What market size did Clearmind cite for weight-loss drugs in the CMND release?

Clearmind cited a market valued at approximately $37 billion in 2025, projected to reach $226 billion by 2035. According to the company, this growth underscores demand for alternatives to GLP-1 agonists.

Is the published PCT application equivalent to a granted patent for Clearmind (CMND)?

No, a PCT publication is an international patent application publication, not a granted patent. According to the company, the publication is a step in the IP process but does not confer an issued patent right.